Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Phase I/II Study to Evaluate the Safety and Efficacy of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor Given in Combination With a Histone Deacetylase (HDAC) Inhibitor, Romidepsin in Adult Patients With Relapsed/Refractory T-cell Lymphoma

NCT03770000 is registered in ClinicalTrials.gov with Rhizen Pharmaceuticals SA as lead sponsor.

NCT NCT03770000
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03770000 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Phase I/II Study to Evaluate the Safety and Efficacy of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor Given in Combination With a Histone Deacetylase (HDAC) Inhibitor, Romidepsin in Adult Patients With Relapsed/Refractory T-cell Lymphoma
Lead sponsor
Rhizen Pharmaceuticals SA
Phase
Phase 1/2
Overall status
Completed
Start date
March 12, 2019
Completion date
May 14, 2021
Enrollment
33 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

t cell lymphoma